Joël Guigay1, Hervé Le Caer2, Cécile Ortholan3, Anne Aupérin4, Cécile Michel5, Cécile Mertens6. 1. Department of Medical Oncology, Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice. 2. Service d'oncologie médicale, Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France. 3. Service d'oncologie - radiothérapie, Centre Hospitalier Princesse-Grace, Monaco. 4. Département d'épidémiologie et de biostatistiques, Gustave-Roussy, Villejuif. 5. GORTEC, CHU Bretonneau, Tours. 6. Service d'oncogériatrie, Institut Bergonié, Bordeaux, France.
Abstract
PURPOSE OF REVIEW: Elderly head and neck cancer (HNC) patients are very rarely enrolled in clinical trials, and even more so in dedicated trials in curative or palliative setting. As a result, no standards of treatment exist for this population and thus, adaptation of standard treatments is commonly used. RECENT FINDINGS: The choice between a monotherapy and a platinum-cetuximab combination is based on the performance status, which is not suitable and/or sufficient to evaluate the patient ability to receive a systemic treatment combined or not with radiotherapy. The evaluation of functional age using geriatric assessment is recommended. However, access to comprehensive geriatric assessment is limited in many centers, and the choice of the type of treatment is often not based on objective and reproducible criteria. As a result, fragile elderly HNC patients may be overtreated with a risk of increased toxicity and fit patients proposed for suboptimal treatment with a risk of failure of tumor control. SUMMARY: It is therefore crucial to develop and evaluate customized treatments by enrolling elderly HNC patients in dedicated therapeutics trials, such as the ELAN (Elderly Head and Neck Cancer) studies or new approaches involving promising immunotherapies. To administer the most suitable therapy, a simple and reproducible geriatric assessment could efficiently guide practitioners.
PURPOSE OF REVIEW: Elderly head and neck cancer (HNC) patients are very rarely enrolled in clinical trials, and even more so in dedicated trials in curative or palliative setting. As a result, no standards of treatment exist for this population and thus, adaptation of standard treatments is commonly used. RECENT FINDINGS: The choice between a monotherapy and a platinum-cetuximab combination is based on the performance status, which is not suitable and/or sufficient to evaluate the patient ability to receive a systemic treatment combined or not with radiotherapy. The evaluation of functional age using geriatric assessment is recommended. However, access to comprehensive geriatric assessment is limited in many centers, and the choice of the type of treatment is often not based on objective and reproducible criteria. As a result, fragile elderly HNCpatients may be overtreated with a risk of increased toxicity and fit patients proposed for suboptimal treatment with a risk of failure of tumor control. SUMMARY: It is therefore crucial to develop and evaluate customized treatments by enrolling elderly HNC patients in dedicated therapeutics trials, such as the ELAN (Elderly Head and Neck Cancer) studies or new approaches involving promising immunotherapies. To administer the most suitable therapy, a simple and reproducible geriatric assessment could efficiently guide practitioners.
Authors: J Martínez-Trufero; A Lozano Borbalas; I Pajares Bernad; M Taberna Sanz; E Ortega Izquierdo; B Cirauqui Cirauqui; J Rubió-Casadevall; M Plana Serrahima; J M Ponce Ortega; I Planas Toledano; J Caballero; J Marruecos Querol; L Iglesias Docampo; J Lambea Sorrosal; J C Adansa; R Mesía Nin Journal: Clin Transl Oncol Date: 2021-04-19 Impact factor: 3.405
Authors: Juan A Marín-Jiménez; Marc Oliva; Paloma Peinado Martín; Santiago Cabezas-Camarero; Maria Plana Serrahima; Gonzalo Vázquez Masedo; Alicia Lozano Borbalas; María N Cabrera Martín; Anna Esteve; María C Iglesias Moreno; Esther Vilajosana Altamis; Lorena Arribas Hortigüela; Miren Taberna Sanz; Pedro Pérez-Segura; Ricard Mesía Journal: Front Oncol Date: 2022-07-22 Impact factor: 5.738
Authors: S S Jeske; P J Schuler; J Doescher; M N Theodoraki; S Laban; C Brunner; T K Hoffmann; M C Wigand Journal: Immun Ageing Date: 2020-02-12 Impact factor: 6.400